Senior MPs urge post-Brexit EU drug regulation deal

Latest news

    Various pillsImage copyright Thinkstock

    The UK will continue to co-operate with the European Union on medicine testing after it leaves the bloc, two senior ministers have suggested.

    Business Secretary Greg Clark and Health Secretary Jeremy Hunt said such a deal would be “in the interests of public health and safety”.

    “The UK would like to find a way to continue to collaborate with the EU,” they wrote in a Financial Times letter.

    There are fears Brexit may cause delays in UK patients getting new drugs.

    Currently the London-based European Medicines Agency (EMA) authorises drugs for use across the EU, including the UK.

    However, it is expected to move out of the UK after Brexit, raising uncertainty over whether the UK will need to develop its own separate drug approval system.

    Industry experts have warned that if this happens pharmaceutical firms could be slower to seek permission for their drugs to be used in just one country, focusing instead on getting their drugs approved for larger, more lucrative markets.

    The UK pharmaceuticals trade association has also warned that Brexit could undermine future investment, research and jobs in the country.

    The ministers wrote that the UK “will look to continue to work closely with the European Medicines Agency (EMA).”

    “Our overall aim is to ensure that patients in the UK and across the EU continue to be able to access the best and most innovative medicines,” they added.

    Image copyright PA
    Image caption Greg Clark said the current UK and EU partnership had been beneficial

    In the letter, they cited examples where the UK and EU partnership had helped patients, including the licensing of 130 products to treat rare diseases.

    In an attempt to reassure the industry, they also said if it wasn’t possible to arrange “our desired relationship with the EU”, then Britain would “set up a regulatory system” to process drugs licenses “as quickly as possible.”

    In April, EMA Executive Director Guido Rasi said continued co-operation was theoretically possible but it would be up to EU governments to decide whether to offer such a deal.

    Pharmaceutical firms have been pushing for some kind of clarity over what the UK’s exit from the EU will mean for the industry.

    View the original article: http://www.bbc.co.uk/news/business-40489359

    Mike Thompson, CEO of the Association of the British Pharmaceutical Industry, said the ministers’ letter was “a welcome recognition that the future of medicines regulation is a key priority for the government”.

    In the same category are

    Commons set for Brexit vote showdown Image copyright PA The row over how much of a say MPs should get in the Brexit process returns to the House of Commons later.On Monday, the House of...
    Rural residents hang up on mobile banking, regulator finds Image copyright Getty Images Consumers in rural areas of the UK are far less likely to use their smartphones for banking than their urban counterpar...
    Newspaper headlines: GCHQ Brexit warning and fizzy drink ‘shortage’ By BBC News Staff Image caption The Guardian says the director of surveillance agency GCHQ has made an unprecedented intervention in a growing r...
    General Electric drops out of Dow index Image copyright Getty Images General Electric is losing its place on the Dow Jones Industrial Average after more than 100 years in a move that refle...
    World Cup 2018: England’s Harry Kane wants to be ‘best in the world’ The making of England's Kane2018 Fifa World Cup on the BBCHost: Russia Dates: 14 June - 15 JulyLive: Coverage across BBC TV, BBC Radio and BBC Sport ...
    The nurses tackling mental illness in police custody An estimated third of those arrested by police in England are experiencing mental health problems.Most police forces now have mental health nurses wor...

    Leave a comment

    Your email address will not be published. Required fields are marked *

    This site uses Akismet to reduce spam. Learn how your comment data is processed.